Since MM was found to over-express L-type amino-acid transporter 1 (LAT1), also in correlation with its grade of proliferation and biological aggressiveness, amino-acid PET with 11C-methionine (MET) has been proposed as a possible alternative to FDG in this clinical setting [11,12]. Here, SLC7A5 is linked to Miyoshi myopathy.